How Does MOTS-c Work? Mechanism of Action, Per the Research

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is one of a small family of peptides encoded not in the nuclear genome but inside mitochondrial DNA. Its mechanism of action is usually described in two layers: a well-replicated metabolic signalling pathway centred on AMPK, and a broader set of proposed actions — nuclear gene regulation, redox control, mitochondrial remodelling — that are still being mapped. This page summarises what published pharmacology reports about each layer, and labels which findings came from cells, animals or humans. For general background on the peptide itself, see the MOTS-c overview.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Nothing here describes how any substance should be used.

Where MOTS-c Comes From

The peptide was identified by researchers searching mitochondrial DNA for short open reading frames of the kind that had already yielded humanin; the study reported a short open reading frame within the mitochondrial 12S rRNA encoding a 16-amino-acid peptide, which the authors named MOTS-c, and described it as regulating insulin sensitivity and metabolic homeostasis (PMID 25738459). Reviews of the mitochondrial-derived peptide (MDP) field place MOTS-c alongside humanin and the SHLP peptides as evidence that mitochondria act as signalling organelles rather than only as energy-producing ones (PMID 31131430).

That origin matters mechanistically. Because MOTS-c is encoded in the mitochondrial genome but acts on cellular and, in some reports, nuclear targets, reviews have described it as a mitokine — a signal sent outward from the mitochondrion to coordinate the rest of the cell and, potentially, other tissues (PMID 32776825).

The Established Core Mechanism: Folate Cycle → Purine Synthesis → AMPK

The most consistently cited mechanism comes from the original characterisation. The study reported that skeletal muscle appeared to be the primary target organ, and that MOTS-c's cellular actions inhibited the folate cycle and its tethered de novo purine biosynthesis, leading to activation of AMP-activated protein kinase (AMPK) (PMID 25738459). In that same work, researchers reported that MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity (PMID 25738459) — findings in rodents, not humans.

Why AMPK is the pivot point is worth unpacking. AMPK is a cellular fuel gauge: when it is switched on, catabolic, ATP-generating pathways are favoured over anabolic, ATP-consuming ones. Reviews of MOTS-c pharmacology describe AMPK activation as the common node linking the peptide to glucose uptake, fatty acid handling and mitochondrial function across the models studied (PMID 36761202). A separate review of MOTS-c in metabolic disorders similarly framed the peptide's reported metabolic actions as downstream of this energy-sensing axis (PMID 36677050).

What "inhibiting the folate cycle" means in practice

The folate (one-carbon) cycle feeds carbon units into purine synthesis. Interrupting that flow causes upstream intermediates to accumulate, and intermediates of this pathway are recognised by AMPK's regulatory machinery. The 2015 characterisation described this metabolic interruption — rather than a classical hormone–receptor binding event — as the proximate cause of AMPK activation by MOTS-c (PMID 25738459). Later reviews have retained this as the canonical description of the peptide's intracellular mechanism (PMID 36761202).

Is There a MOTS-c Receptor?

This is where the literature is explicitly incomplete. Unlike peptide hormones with well-defined G-protein-coupled receptors, MOTS-c has not been assigned a single, definitively established cell-surface receptor in the published reviews; instead, reviews describe uptake into cells and intracellular metabolic interference as the operative step, with cell-surface binding partners remaining an open research question (PMID 36761202). Broader MDP reviews make the same point for the peptide family as a whole, noting that receptor identification lags behind the functional observations (PMID 31131430).

One mechanistically specific finding has been reported for intracellular trafficking rather than surface binding: a 2025 study described MOTS-c attenuating lung ischemia–reperfusion injury via MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes (PMID 40403491). That work identified a protein partner involved in moving the peptide to the nucleus — a different kind of "target" from a receptor, and one demonstrated in an injury model rather than in healthy humans.

Nuclear Signalling and Stress-Response Genes

Beyond AMPK, several papers describe MOTS-c entering the nucleus under metabolic stress and influencing transcription. The 2025 lung ischemia–reperfusion study reported transcriptional activation of antioxidant genes following nuclear translocation (PMID 40403491), and review articles describe this nuclear retrograde signalling as a defining feature that separates MOTS-c from conventional cytoplasmic metabolic regulators (PMID 36761202). Reviews of MDPs in energy metabolism have framed the same concept as mitochondria-to-nucleus communication (PMID 32776825).

Downstream Physiology Described in the Literature

Skeletal muscle and glucose handling

The original study identified skeletal muscle as the apparent primary target organ and reported effects on insulin sensitivity in mice (PMID 25738459). At the cellular level, a 2022 study reported that MOTS-c promoted muscle differentiation in vitro (PMID 35842023) — a cell-culture observation, not a demonstration of muscle growth in people. A review of MOTS-c in metabolic disorders summarised the animal and cell evidence linking the peptide to glucose and lipid handling (PMID 36677050).

Exercise and the mitokine hypothesis

A 2021 review examined mitochondrial-derived peptides in the context of exercise, describing circulating MDP responses to exercise and the proposal that these peptides participate in the adaptive response to physical activity (PMID 34520826). This is a correlation-and-model literature rather than evidence that administering the peptide reproduces exercise adaptations.

Glycolytic reprogramming in injury models

A 2025 animal study reported that MOTS-c promoted glycolysis via an AMPK–HIF-1α–PFKFB3 pathway and ameliorated cardiopulmonary bypass-induced lung injury (PMID 40035775). Here AMPK sits upstream of a transcription factor (HIF-1α) and a glycolytic regulator (PFKFB3), illustrating how the same energy-sensing node can branch into tissue-specific outcomes.

Fibrosis and antiviral observations

A 2023 paper discussed MOTS-c as a potential anti-pulmonary fibrosis factor derived from mitochondria, summarising preclinical signalling evidence (PMID 37307934). Separately, a 2024 study reported a function for MOTS-c in mitochondrial remodelling that contributed to an antiviral role during hepatitis B virus infection (PMID 37788894). Both are mechanistic and preclinical; neither establishes a treatment.

Established vs. Proposed: A Side-by-Side

Why Mechanism Does Not Equal Outcome

A plausible pathway in a mouse or a dish is a hypothesis about humans, not a conclusion. Reviews calling MOTS-c "promising for therapeutic exploitation" are explicit that the work remains largely preclinical and that translation requires human trials (PMID 36761202). The broader MDP review literature makes the same caveat about the peptide family (PMID 31131430). Several practical gaps follow from that: how much intact peptide reaches target tissues after administration, how long it persists, and whether the pathways observed in injury models are engaged in healthy physiology are all questions the cited reviews treat as unresolved (PMID 32776825).

Mechanism-Related Safety and Regulatory Status: What Studies Report

A 2026 review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance examined safety and efficacy evidence across this class and reported that many peptides circulating in performance contexts lack regulatory approval and adequately powered human safety data (PMID 41966639). No adverse-event profile for MOTS-c in humans is characterised in the verified papers summarised here; the mechanistic studies cited above reported cellular and animal findings rather than clinical tolerability outcomes (PMID 36761202). Because AMPK is a near-universal energy sensor, reviews note that pathway-level interventions have system-wide reach — a reason mechanism-only reasoning is a poor substitute for trial data (PMID 36677050).

Key Points

• MOTS-c is a 16-amino-acid peptide encoded within mitochondrial 12S rRNA, identified in 2015 (PMID 25738459).
• Its best-supported mechanism is folate-cycle and purine-synthesis inhibition leading to AMPK activation, with skeletal muscle described as the apparent primary target organ (PMID 25738459).
• Nuclear translocation and transcriptional effects on antioxidant genes have been reported in an animal injury model (PMID 40403491).
• No single cell-surface receptor is established in the reviewed literature (PMID 36761202).
• Human clinical evidence is limited, and regulatory approval is absent for performance-related peptide use per a 2026 review (PMID 41966639).

References

• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• MOTS-c Functionally Prevents Metabolic Disorders (Metabolites, 2023)
• Mitochondrial-derived peptides in energy metabolism (American Journal of Physiology: Endocrinology and Metabolism, 2020)
• Mitochondrial-derived peptides and exercise (Biochimica et Biophysica Acta: General Subjects, 2021)
• Mitochondrial peptides-appropriate options for therapeutic exploitation (Cell and Tissue Research, 2019)
• MOTS-c promotes muscle differentiation in vitro (Peptides, 2022)
• MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury (American Journal of Respiratory Cell and Molecular Biology, 2025)
• MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes (Redox Biology, 2025)
• MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria (Mitochondrion, 2023)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)